Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Buy
60
TNDM Quote, Financials, Valuation and Earnings
Last price:
$36.96
Seasonality move
:
12.65%
Day range:
$35.16 - $36.65
52-week range:
$21.85 - $53.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.80x
P/B ratio:
10.11x
Volume:
932.8K
Avg. volume:
1.4M
1-year change:
24.14%
Market cap:
$2.4B
Revenue:
$747.7M
EPS (TTM):
-$1.93
Analysts' Opinion
-
Consensus RatingTandem Diabetes Care has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Tandem Diabetes Care has an estimated upside of 39.31% from its current price of $36.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $36.61.
Fair Value
-
According to the consensus of 12 analysts, Tandem Diabetes Care has 39.31% upside to fair value with a price target of -- per share.
TNDM vs. S&P 500
-
Over the past 5 trading days, Tandem Diabetes Care has overperformed the S&P 500 by 7.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Tandem Diabetes Care does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Tandem Diabetes Care has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Tandem Diabetes Care reported revenues of $244M.
Earnings Growth
-
Tandem Diabetes Care earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Tandem Diabetes Care reported earnings per share of -$0.35.
Enterprise value:
2.3B
EV / Invested capital:
3.89x
Price / LTM sales:
2.80x
EV / EBIT:
--
EV / Revenue:
2.67x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-61.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$425.4M
Return On Assets:
-13.41%
Net Income Margin (TTM):
-14.84%
Return On Equity:
-47.23%
Return On Invested Capital:
-21.45%
Operating Margin:
-10.7%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $790.7M | $771.4M | $854.4M | $185.6M | $244M | |
| Gross Profit | $411.2M | $389.9M | $425.4M | $89.8M | $124.7M | |
| Operating Income | -$31.3M | -$215.9M | -$133.6M | -$31.5M | -$26.1M | |
| EBITDA | -$47.1M | -$181.8M | -$100.8M | -$22.6M | -$16.5M | |
| Diluted EPS | -$1.07 | -$3.23 | -$1.93 | -$0.51 | -$0.35 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $592.3M | $754.9M | $834.3M | $758.1M | $752.8M | |
| Total Assets | $673M | $850.3M | $1B | $939.9M | $957.7M | |
| Current Liabilities | $105.5M | $119.7M | $173.6M | $187.1M | $259.3M | |
| Total Liabilities | $346.4M | $460.6M | $625.7M | $625.9M | $720M | |
| Total Equity | $326.5M | $389.7M | $421.8M | $314M | $237.7M | |
| Total Debt | $199.1M | $281M | $282.8M | $284.6M | $348.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $64.3M | -$18.8M | $6.3M | $55K | $26.8M | |
| Cash From Investing | -$79.4M | -$33.4M | -$45.1M | -$48.5M | -$19.9M | |
| Cash From Financing | $26.7M | $7.6M | $8.7M | -$1.9M | -$4.5M | |
| Free Cash Flow | $21.2M | -$48.5M | -$37.4M | -$5.3M | $21.5M | |
TNDM
Sector
Market Cap
$2.4B
$45.6M
Price % of 52-Week High
68.19%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
24.14%
-31.35%
Beta (5-Year)
1.324
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$34.20
200-day SMA
Sell
Level
$38.77
Bollinger Bands (100)
Sell
Level
31.92 - 42.74
Chaikin Money Flow
Buy
Level
43.7M
20-day SMA
Buy
Level
$32.75
Relative Strength Index (RSI14)
Buy
Level
62.66
ADX Line
Buy
Level
17.42
Williams %R
Sell
Level
-0.5579
50-day SMA
Buy
Level
$32.49
MACD (12, 26)
Buy
Level
0.79
25-day Aroon Oscillator
Buy
Level
96
On Balance Volume
Neutral
Level
111.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.1662)
Sell
CA Score
(Annual)
Level (-1.699)
Buy
Beneish M-Score
(Annual)
Level (-3.205)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.725)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Stock Forecast FAQ
In the current month, TNDM has received 5 Buy ratings 7 Hold ratings, and 0 Sell ratings. The TNDM average analyst price target in the past 3 months is --.
-
Where Will Tandem Diabetes Care Stock Be In 1 Year?
According to analysts, the consensus estimate is that Tandem Diabetes Care share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Tandem Diabetes Care?
Analysts are divided on their view about Tandem Diabetes Care share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Tandem Diabetes Care is a Sell and believe this share price will drop from its current level to --.
-
What Is Tandem Diabetes Care's Price Target?
The price target for Tandem Diabetes Care over the next 1-year time period is forecast to be -- according to 12 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is TNDM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Tandem Diabetes Care is a Hold. 7 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TNDM?
You can purchase shares of Tandem Diabetes Care via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Tandem Diabetes Care shares.
-
What Is The Tandem Diabetes Care Share Price Today?
Tandem Diabetes Care was last trading at $36.96 per share. This represents the most recent stock quote for Tandem Diabetes Care. Yesterday, Tandem Diabetes Care closed at $36.61 per share.
-
How To Buy Tandem Diabetes Care Stock Online?
In order to purchase Tandem Diabetes Care stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.07% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 1.39% over the past day.
